Potent Anti-leukemia activities of Chimeric antigen Receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia

Clinical Cancer Research

Volumn 23, Issue 13, 2017, Pages 3297-3306

  Hu, Yongxian ^a   Wu, Zhao ^b   Luo, Yi ^a   Shi, Jimin ^a   Yu, Jian ^a   Pu, Chengfei ^b   Liang, Zuyu ^a   Wei, Guoqing ^a   Cui, Qu ^c   Sun, Jie ^a   Jiang, Jing ^b   Xie, Jue ^d   Tan, Yamin ^a   Ni, Wanmao ^e   Tu, Jifang ^a   Wang, Jinping ^b   Jin, Aiyun ^a   Zhang, Hao ^a   Cai, Zhen ^a   Xiao, Lei ^b   Huang, He ^a   more..

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Formerly SiDanSai Biotechnology Co   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; D DIMER; FERRITIN; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MANNITOL; METHYLPREDNISOLONE; TISAGENLECLEUCEL T; TOCILIZUMAB; TUMOR NECROSIS FACTOR; CD19 ANTIGEN; CD19 MOLECULE, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLURRED VISION; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGRESSION; CELL EXPANSION; CHINESE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONFUSION; CYTOKINE RELEASE SYNDROME; DISEASE FREE SURVIVAL; DRUG SAFETY; EPILEPSY; FACIAL NERVE PARALYSIS; FEVER; GAIT DISORDER; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; MYALGIA; NEUROTOXICITY; OVERALL SURVIVAL; PANCYTOPENIA; PAPILLEDEMA; PARALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REFRACTORY ACUTE LYMPHOCYTIC LEUKEMIA; RELAPSED ACUTE LYMPHOCYTIC LEUKEMIA; SIDE EFFECT; T LYMPHOCYTE; TRANSPLANTATION CONDITIONING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL FIELD DEFECT; VOMITING; CHINA; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; REMISSION;

ADULT; ANTIGENS, CD19; CHINA; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; REMISSION INDUCTION; T-LYMPHOCYTES;

EID: 85021755863     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1799     Document Type: Article

References (41)

1. Gokbuget € N, Stanze D, Beck J, Diedrich H, Horst HA, Huttmann € A, et al. German Multicenter Study Group for Adult Acute Lympho-blastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120:2032–41.
2. O'Brien S, Schiller G, Lister J, Damon L, Goldberg S, Aulitzky W, et al. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 2013;31:676–83.
3. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010;116:5568–74.
4. Imamura M, Shigematsu A. Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning. Exp Hematol Oncol 2015;4:20.
5. Kako S, Kanamori H, Kobayashi N, Shigematsu A, Nannya Y, Nakamae M, et al. Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia. Br J Haematol 2013;161:95–103.
6. De Astis E, Clavio M, Raiola AM, Ghiso A, Guolo F, Minetto P, et al. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. Ann Hematol 2014;93:2011–8.
7. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst 2016;108: pii: djv439.
8. Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol 2016;34:1112–21.
9. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517–28.
10. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224ra25.1.
11. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8þ and CD4þ subsets confer superior antitumor reactivity in vivo. Leukemia 2016;30:492–500.
12. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–17.
13. Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 2016;127:3312–20.
14. Kenderian SS, Porter DL, Gill S. Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the cart before the horse. Biol Blood Marrow Transplant. 2016 Sep 13. [Epub ahead of print].
15. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013;122:2965–73.
16. Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 2015;4:e1027469.
17. Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. Clin Cancer Res 2016;22:1875–84.
18. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123: 2625–35.
19. Zola H, MacArdle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol Cell Biol 1991;69:411–22.
20. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004;18:676–84.
21. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365: 725–33.
22. Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol 2016;9:70.
23. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3: 95ra73.
24. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95.
25. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–18.
26. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38.
27. Haji-Fatahaliha M, Hosseini M, Akbarian A, Sadreddini S, Jadidi-Niaragh F, Yousefi M. CAR-modified T-cell therapy for cancer: an updated review. Artif Cells Nanomed Biotechnol 2016;44:1339–49.
28. Park JH, Geyer MB, Brentjens RJ. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 2016;127:3312–20.
29. Zhang T, Cao L, Xie J, Shi N, Zhang Z, Luo Z, et al. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis. Oncotarget 2015;6:33961–71.
30. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4þ:CD8þ composition in adult B cell ALL patients. J Clin Invest 2016;126:2123–38.
31. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. ChimericantigenreceptorTcellspersistandinducesustainedremissionsin relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7:303ra139.
32. Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013;121:5154–7.
33. Bugelski PJ, Achuthanandam R, Capocasale RJ, Treacy G, Bouman-Thio E. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev Clin Immunol 2009;5:499–521.
34. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664–79.
35. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 206;127:3321–30.
36. Maus MV, Powell DJ Jr. Chimeric antigen receptor T-cells: new approaches to improve their efficacy and reduce toxicity. Cancer J 2015;21:475–9.
37. Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol 2015; 12:344–57.
38. Paguirigan AL, Smith J, Meshinchi S, Carroll M, Maley C, Radich JP. Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia. Sci Transl Med 2015;7:281re2.
39. Sood R, Hansen NF, Donovan FX, Carrington B, Bucci D, Maskeri B, et al. Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia. Leukemia 2016;30:501–4.
40. Hu YX, Cui Q, Liang B, Huang H. Relapsing hematologic malignancies after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1099–111.
41. Luo Y, Xiao H, Lai X, Shi J, Tan Y, He J, et al. T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. Blood 2014;23:2735–43.